HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Milano, A. Articles by Gallucci, V. Search for Related Content PubMed PubMed Citation Articles by Milano, A. Articles by Gallucci, V.

The Journal of Thoracic and Cardiovascular Surgery, Vol 103, 267-275, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Heart valve replacement with the Sorin tilting-disc prosthesis. A 10- year experience

A Milano, U Bortolotti, A Mazzucco, E Mossuto, L Testolin, G Thiene and V Gallucci
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.

From 1978 to 1988, 697 patients with a mean age of 48 +/- 11 years (range 5 to 75 years) received a Sorin tilting-disc prosthesis; 358 had had aortic valve replacement, 247 mitral valve replacement, and 92 mitral and aortic valve replacement. Operative mortality rates were 7.8%, 11.3%, and 10.8%, respectively, in the three groups. Cumulative duration of follow-up is 1650 patient-years for aortic valve replacement (maximum follow-up 11.4 years), 963 patient-years for mitral valve replacement (maximum follow-up 9.9 years) and 328 patient- years for mitral and aortic valve replacement (maximum follow-up 9.4 years). Actuarial survival at 9 years is 72% +/- 4% after mitral valve replacement, 70% +/- 3% after aortic valve replacement, and 50% +/- 12% after mitral and aortic valve replacement, and actuarial freedom from valve-related deaths is 97% +/- 2% after mitral valve replacement, 92% +/- 2% after aortic valve replacement, and 62% +/- 15% after mitral and aortic valve replacement. Thromboembolic events occurred in 21 patients with aortic valve replacement (1.3% +/- 0.2%/pt-yr), in 12 with mitral valve replacement (1.2% +/- 0.3% pt-yr), and in seven with mitral and aortic valve replacement (2.1% +/- 0.8%), with one case of prosthetic thrombosis in each group; actuarial freedom from thromboembolism at 9 years is 92% +/- 3% after mitral valve replacement, 91% +/- 3% after aortic valve replacement, and 74% +/- 16% after mitral and aortic valve replacement. Anticoagulant-related hemorrhage was observed in 15 patients after aortic valve replacement (0.9% +/- 0.2%/pt-yr), in 9 after mitral valve replacement (0.9% +/- 0.3%/pt-yr), and in 6 with mitral and aortic valve replacement (0.9% +/- 0.5%/pt-yr); actuarial freedom from this complication at 9 years is 94% +/- 2% after aortic valve replacement, 91% +/- 4% after mitral valve replacement, and 68% +/- 16% after mitral and aortic valve replacement. Actuarial freedom from reoperation at 9 years is 97% +/- 2% after mitral and aortic valve replacement, 92% +/- 4% after mitral valve replacement, and 89% +/- 3% after aortic valve replacement, with no cases of mechanical fracture. The Sorin valve has shown a satisfactory long-term overall performance, comparable with other mechanical prostheses, and an excellent durability that renders it a reliable heart valve substitute for the mitral and aortic positions.

This article has been cited by other articles:

				N. D. Desai and G. T. Christakis Bioprosthetic Aortic Valve Replacement: Stented Pericardial and Porcine Valves Card. Surg. Adult, January 1, 2008; 3(2008): 857 - 894. [Full Text]

				H. V. Schaff and R. M. Suri Multiple Valve Disease Card. Surg. Adult, January 1, 2008; 3(2008): 1129 - 1158. [Full Text]

				R. Vink, R. A. Kraaijenhagen, B. A. Hutten, R. B. A. van den Brink, B. A. de Mol, H. R. Buller, and M. Levi The optimal intensity of vitamin k antagonists in patients with mechanical heart valves: A meta-analysis J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2042 - 2048. [Abstract] [Full Text] [PDF]

				J.B. Borman and C. De Riberolles Sorin BicarbonTM bileaflet valve: a 10-year experience Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 86 - 92. [Abstract] [Full Text] [PDF]

				N. D. Desai and G. T. Christakis Stented Mechanical/Bioprosthetic Aortic Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 825 - 856. [Full Text]

				H. V. Schaff and D. H. Marsh Multiple Valve Disease Card. Surg. Adult, January 1, 2003; 2(2003): 1017 - 1045. [Full Text]

				S. Torregrosa, J. Gomez-Plana, F. J. Valera, J. Caffarena, J. M. Maronas, F. Garcia-Sanchez, J. Peris, R. Frias, and J. M. Caffarena Long-term clinical experience with the omnicarbon prosthetic valve Ann. Thorac. Surg., September 1, 1999; 68(3): 881 - 886. [Abstract] [Full Text] [PDF]

				J.B. Borman, W.G.B. Brands, L. Camilleri, M. Cotrufo, W. Daenen, I. Gandjbakhch, C. Infantes, A. Khayat, F. Laborde, A. Pellegrini, et al. Bicarbon valve - European multicenter clinical evaluation Eur. J. Cardiothorac. Surg., June 1, 1999; 13(6): 685 - 693. [Abstract] [Full Text] [PDF]

				A. E. Fiane, K. Saatvedt, J. L. Svennevig, O. Geiran, K. Nordstrand, and T. Froysaker The CarboMedics Valve: Midterm Follow-up With Analysis of Risk Factors Ann. Thorac. Surg., October 1, 1995; 60(4): 1053 - 1058. [Abstract] [Full Text]